Tuberculosis Testing for NTM Patients

Trial Objective

Tuberculosis Testing for NTM PatientsThe purpose of this study is to determine if a new blood test known as the VIDAS Interferon Gamma Release Assay (VIDAS TB-IGRA) is effective at diagnosing tuberculosis (TB) in people with nontuberculous mycobacteria (NTM). The study will evaluate whether nontuberculous mycobacteria interfere with the positive Mycobacterium tuberculosis diagnosis. Researchers are comparing VIDAS TB-IGRA with other diagnostic tests known to accurately detect latent tuberculosis in NTM patients. It is important to rule out a TB infection when treating NTM.

Enrollment

New enrollment for this trial is temporarily paused

Who Can Participate

People with suspected NTM infection based on clinical symptoms and/or early diagnostic evidence may be eligible for this study.

Age: 18+    Gender: Any Gender


Estimated Time Commitment

Up to 2 clinic visits



Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Not Available

Trial Contact

For more information, contact:

Megan Rosa

Megan Rosa
303.270.2615

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

bioMerieux

Principal Investigators

Co-Investigators


Request More Information

Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for all trials requiring an in-person visit. Please feel free to request additional information about any of the trials we have posted and we will get back to you when enrollment resumes. For more resources and information on COVID-19 please visit our special coronavirus website at www.njhealth.org/coronavirus.


*
*
*
*